Canine Osteosarcoma Clinical Trial
- Trial enrollment is required prior to amputation (affected limb must be intact)
- Treatment includes either ECI immunotherapy or carboplatin chemotherapy
- Patients must complete a 7-11 week treatment regimen and return for quarterly follow-up visits throughout the 18-month trial
- Study sponsor will cover treatment costs (including consult with oncologist, radiographs, lab work, ECI immunotherapy or carboplatin chemotherapy treatment, and their administration)
- Inclusion Criteria:
- Appendicular osteosarcoma with the limb still in place
- Patient determined to be insufficiently good health overall to undergo and complete the treatment schedule
- Is not currently pregnant or lactating
- Has not previously received any treatments for its cancer
- Does not have metastatic disease (tumor spread) at the time of diagnosis
- Is not currently on immunosuppressive drugs
- Is not currently taking any supplements, herbal products, or other natural remedies for its cancer or other health-related issues
- Does not have a second malignancy
- Must weigh at least 15 kg
- Owner/guardian is willing and able to take the dog to all scheduled clinic visits during the treatment schedule, as well as the follow-up visits.
Prior to acceptance into any trial, all candidates are required to have a consultation to determine eligibility. The fee for the consultation is the responsibility of the pet owner.
Visit this link for more information about current pet clinical trials: American Veterinary Medical Association's Animal Health Studies Database.